IL292465B2 - Neuroactive compounds and methods of use thereof - Google Patents

Neuroactive compounds and methods of use thereof

Info

Publication number
IL292465B2
IL292465B2 IL292465A IL29246522A IL292465B2 IL 292465 B2 IL292465 B2 IL 292465B2 IL 292465 A IL292465 A IL 292465A IL 29246522 A IL29246522 A IL 29246522A IL 292465 B2 IL292465 B2 IL 292465B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
hhh
ohhh
Prior art date
Application number
IL292465A
Other languages
English (en)
Hebrew (he)
Other versions
IL292465B1 (en
IL292465A (en
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of IL292465A publication Critical patent/IL292465A/en
Publication of IL292465B1 publication Critical patent/IL292465B1/en
Publication of IL292465B2 publication Critical patent/IL292465B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL292465A 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof IL292465B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07
PCT/US2015/054551 WO2016057713A1 (en) 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof

Publications (3)

Publication Number Publication Date
IL292465A IL292465A (en) 2022-06-01
IL292465B1 IL292465B1 (en) 2025-02-01
IL292465B2 true IL292465B2 (en) 2025-06-01

Family

ID=55653736

Family Applications (2)

Application Number Title Priority Date Filing Date
IL292465A IL292465B2 (en) 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof
IL251505A IL251505B (en) 2014-10-07 2017-04-02 Neuroactive compounds and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL251505A IL251505B (en) 2014-10-07 2017-04-02 Neuroactive compounds and methods of using them

Country Status (17)

Country Link
US (2) US20170304321A1 (enExample)
EP (1) EP3204011A4 (enExample)
JP (3) JP2017530982A (enExample)
KR (1) KR20170065637A (enExample)
CN (2) CN107405352A (enExample)
AU (2) AU2015330906A1 (enExample)
BR (1) BR112017007053A2 (enExample)
CA (1) CA2963938C (enExample)
IL (2) IL292465B2 (enExample)
MX (2) MX388694B (enExample)
MY (1) MY202135A (enExample)
PE (1) PE20170907A1 (enExample)
PH (1) PH12017500639A1 (enExample)
RU (1) RU2764702C2 (enExample)
SG (2) SG11201702799UA (enExample)
WO (1) WO2016057713A1 (enExample)
ZA (1) ZA201702545B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SMT202200094T1 (it) 2013-12-24 2022-05-12 Univ Virginia Commonwealth Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
JP6882996B2 (ja) * 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
SMT202100476T1 (it) 2015-07-06 2021-09-14 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
WO2018026781A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
MX392270B (es) 2016-09-30 2025-03-24 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN110267966B (zh) * 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001097A2 (en) * 2007-06-27 2008-12-31 Isis Innovation Limited Substrate reduction therapy
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20110118353A1 (en) * 2007-11-06 2011-05-19 N. V. Organon Method of hormone suppression in humans
CA2722776A1 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
WO2013036835A1 (en) * 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP2841067A4 (en) * 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
AU2014212487C1 (en) * 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015195967A1 (en) * 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) * 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
JP6882996B2 (ja) * 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2009001097A2 (en) * 2007-06-27 2008-12-31 Isis Innovation Limited Substrate reduction therapy
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOSTER, PS ET AL.,, EFFECT OF STEROIDS ON 13-ADRENOCEPTOR-MEDIATED RELAXATION OF PIG BRONCHUS., 31 December 1983 (1983-12-31) *
STAMP, TCB ET AL.,, PLASMA LEVELS AND THERAPEUTIC EFFECT OF 25-HYDROXYCHOLECALCIFEROL IN EPILEPTIC PATIENTS TAKING ANTICONVULSANT DRUGS., 31 December 1972 (1972-12-31) *
TIERNEY, E ET AL, ABNORMALITIES OF CHOLESTEROL METABOLISM IN AUTISM SPECTRUM DISORDERS." ,, 5 September 2006 (2006-09-05) *

Also Published As

Publication number Publication date
MY202135A (en) 2024-04-05
CA2963938C (en) 2023-10-24
AU2015330906A1 (en) 2017-04-27
RU2764702C2 (ru) 2022-01-19
JP2020196759A (ja) 2020-12-10
IL292465B1 (en) 2025-02-01
AU2021200721B2 (en) 2023-06-01
ZA201702545B (en) 2019-06-26
MX2017004684A (es) 2017-06-30
CN107405352A (zh) 2017-11-28
US20170304321A1 (en) 2017-10-26
SG11201702799UA (en) 2017-05-30
PE20170907A1 (es) 2017-07-12
NZ730862A (en) 2024-01-26
JP2017530982A (ja) 2017-10-19
MX2021011939A (es) 2021-11-03
WO2016057713A1 (en) 2016-04-14
JP2022033285A (ja) 2022-02-28
EP3204011A4 (en) 2018-06-20
MX388694B (es) 2025-03-20
IL292465A (en) 2022-06-01
IL251505A0 (en) 2017-05-29
US20230218638A1 (en) 2023-07-13
KR20170065637A (ko) 2017-06-13
PH12017500639A1 (en) 2017-09-25
EP3204011A1 (en) 2017-08-16
RU2017115849A3 (enExample) 2019-05-15
IL251505B (en) 2022-05-01
RU2017115849A (ru) 2018-11-13
CA2963938A1 (en) 2016-04-14
BR112017007053A2 (pt) 2018-06-19
SG10202011773UA (en) 2021-01-28
AU2021200721A1 (en) 2021-03-04
CN112121171A (zh) 2020-12-25

Similar Documents

Publication Publication Date Title
IL292465B2 (en) Neuroactive compounds and methods of use thereof
JP2016518337A5 (enExample)
JP2015517488A5 (enExample)
JP2016515561A5 (enExample)
JP2012193216A5 (enExample)
JP2014218522A5 (enExample)
JP2014111603A5 (enExample)
JP2016515522A5 (enExample)
JO3603B1 (ar) مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
JP2015057451A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2015078230A5 (enExample)
JP2013525444A5 (enExample)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2015534562A5 (enExample)
JP2016510326A5 (enExample)
JP2016539125A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
HRP20191744T1 (hr) 1-[2-(aminometil)benzil]-2-tiokso-1,2,3,5-tetrahidro-4h-pirolo[3,2-d]pirimidin-4-oni kao inhibitori mijeloperoksidaze
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2013166781A5 (enExample)
JP2016537338A5 (enExample)
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
JP2016515550A5 (enExample)